A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Health Economics Review

Volumn 3, Issue 1, 2013, Pages 1-12

  Bentley, Anthony ^a   Filipovic, Ivana ^b   Gooch, Katherine ^b   Büsch, Katharina ^b  

^a Decision Resources Group   (United Kingdom)

^b ABBVIE INC   (United States)

Author keywords

Cost effectiveness; Palivizumab; Prophylaxis; Respiratory syncytial virus; United Kingdom

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE SEVERITY; DRUG COST; ENVIRONMENTAL FACTOR; GESTATIONAL AGE; HEALTH CARE COST; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; LIFE EXPECTANCY; PREMATURITY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SENSITIVITY ANALYSIS; UNITED KINGDOM;

EID: 85015333503     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-18     Document Type: Article

References (35)

1. Department of Health: Joint Committee on Vaccination and Immunisation Statement on immunisation for Respiratory Syncytial Virus. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_120395.pdf. Accessed 31 July 2013.
2. Food and Drug Administration: Palivizumab: Annotated Clinical Review of Biological License Application; 1998. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093366.htm. Accessed 21 September 2011.
3. Despande S, Northern V: The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003, 88:1065-1069.
4. Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS: Contribution of RSV to bronchiolitis and pneumonia-associated hospitalisations in English children, April 1995-March 1998. Epidemiol Infec 2002, 129(1):99-106.
5. Feltes TF, Cabalka AK, Meissner HC, et al: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.
6. IMPACT Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102:531-537.
7. electronic Medicines Compendium: SYNAGIS 50 mg or 100 mg powder and solvent for solution for injection - SPC. http://www.medicines.org.uk/EMC/medicine/5676/SPC/Synagis (2010). Accessed 21 September 2011.
8. Martinez F: Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003, 22(2 Suppl):S76-S82.
9. Openshaw PJ, Dean GS, Culley FJ: Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J 2003, 22(2 Suppl): S58-S64. discussion S64-5.
10. Hall CB, Weinberg GA, Iwane MK, et al: The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
11. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P: Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. Clin Virol 2011, 52(3):215-221.
12. Nuijten MJ, Wittenberg W, Lebmeier M: Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. PharmacoEconomics 2007, 25:55-71.
13. Wang D, Bayliss S, Meads C: Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modeling of subgroup analyses. Health Technol Assess 2011, 15: 1-124. iii-iv.
14. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A: Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008, 12:1-86. iii, ix-x.
15. Yount LE, Mahle WT: Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004, 114:1606-1611.
16. Feltes CSR: A Study of the Safety, Tolerance, and Efficacy of Palivizumab (MEDI-492, Synagis®) for Prophylaxis of Respiratory Synctial Virus in Children with Congenital Heart Disease. Report: Integrated Clinical and Statistical; 2002.
17. IMPACT Clinical Study Report: A Pivotal Phase III Study of MEDI-493, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, for the Prophylaxis of Severe RSV Disease in Premature Infants and Infants with Bronchopulmonary Dysplasis (BPD). Integrated Clinical and Statistical Report; 1997.
18. Burls A, Sandercock J: Decision-making under conditions of uncertainty what can we learn from palivizumab? Acta Paediatr 2011, 100:1302-1305.
19. World Health Organization: Multicentre Growth Reference Study Group, WHO Child Growth Standards: Length/Height-for-age, Weight-for-age, Weight-for-length, Weight-for-height and Body Mass Index-for age. Methods and Development. Geneva: World Health Organization. http://www.who.int/childgrowth/standards/technical_report/en/index.html (2006). Accessed 2 October 2012.
20. World Health Organization: Multicentre Growth Reference Study Group, WHO Child Growth Standards: Head circumference-for-age, arm circumference-forage, triceps skinfold-for-age and subscapular skinfold-for age. Methods and Development. Geneva: World Health Organization. http://www.who.int/childgrowth/standards/second_set/technical_report_2/en/index.html (2007). Accessed 2 October 2012.
21. Greenough A, Alexander J, Burgess S, et al: Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004, 89:673-678.
22. Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A: RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr 2012, 171:1055-1061.
23. National Institute for Clinical Excellence: Guide to the methods of technology appraisal; 2004. http://www.nice.org.uk. Accessed 9 September 2011.
24. Greenough A, Cox S, Alexander J, et al: Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001, 85:463-468.
25. Office for National Statistics: Expectation of life (in years) at birth selected ages, 1971 onwards: Population Trends; 2011. http://www.statistics.gov.uk Accessed 9 September 2011.
26. Wren C, O'Sullivan JJ: Survival with congenital heart disease and need for follow up in adult life. Heart 2001, 85:438-443.
27. Synagis: In Monthly Index of Medical Specialities (MIMS); 2011. Retrieved at http://www.mims.co.uk/.
28. Department of Health: NHS Reference costs; 2009. https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010 (2010). Accessed 31 July 2013.
29. Curtis L: Unit Costs of Health and Social Care 2010. Canterbury, UK: Personal Social Services Research Unit; 2010.
30. Carbonell-Estrany X, Quero J, Bustos G, et al: Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000, 19:592-597.
31. Carbonell-Estrany X, Figueras-Aloy J, Law BJ: Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004, 23:S193-S201.
32. Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA: Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006, 25:201-207.
33. Sampalis JS, Langley J, Carbonell-Estrany X, et al: Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008, 28:471-480.
34. National Institute for Health and Clinical Excellence (NICE): NICE clinical guideline 117: Turberculosis; 2011. http://www.nice.org.uk/cg117 (2013). Accessed 31 July 2013.
35. Wu HP, Pfarr DS, Losonsky GA, Kiener PA: Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008, 317:103-123.